Skip to main content

Table 3 Association of angiogenesis inhibitor concentrations with plaque burden measured as total percent area stenosis

From: Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden

Factor (median [IQR])

Q1

Q2

Q3

Q4

P value

2.16–3.78 %

3.86–4.95 %

4.96–6.37 %

6.39–13.2 %

n = 31

n = 30

n = 31

n = 30

 

Endostatin (ng/mL)

136.75 [83.51, 198.57]

134.87 [103.91, 191.11]

109.08 [83.17, 184.55]

118.38 [92.03, 150.14]

0.50

ADMA (μmol/L)

0.47 [0.40, 0.54]

0.43 [0.40, 0.51]

0.47 [0.41, 0.50]

0.48 [0.44, 0.56]

0.57

Thrombospondin-2 (pg/mL)

20,900.0 [14,800.0, 26,500.0]

21,000.0 [15,400.0, 33,000.0]

19,100.0 [15,200.0, 26,300.0]

26,000.0 [16,450.0, 33,900.0]

0.45

Endoglin (ng/mL), mean ± SD

4.43 ± 1.49

4.50 ± 1.08

3.91 ± 0.84

4.47 ± 1.23

0.18

Angiopoietin-2 (ng/mL)

2.08 [1.50, 3.11]

2.75 [1.51, 4.48]

2.45 [1.47, 4.86]

2.23 [1.71, 4.44]

0.79

  1. Quartiles of plaque burden and distribution of mean or median values for endostatin (n = 115), thrombospondin-2 (n = 109), endoglin (n = 116), angiopoietin-2 (n = 108), and ADMA (asymmetric dimethyl arginine, n = 110) concentrations